Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor and Ibrutinib in R/R CLL or Aggressive NHL
NCT02303392Phase 1Completed
- Start
- Jun 2015
- Primary completion
- Apr 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of selinexor in chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), B-cell prolymphocytic leukemia (B-PLL) and 3 more. Primary endpoint: Maximum Tolerated Dose for Selinexor at 28 days. Started Jun 2015; status: completed.
02
Drugs
selinexor
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)B-cell prolymphocytic leukemia (B-PLL)non-Hodgkin lymphoma (NHL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02303392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02303392.